Ghent, Belgium; 22 November 2006 – Peakadilly NV, the
predictive protein biomarkers company, has announced that it has changed its
name to Pronota NV, effective immediately. Following the recent close of
series A financing at €14.5 million ($18.4 million), the company is increasing
capacity of both equipment and employees, and the name change is part of its
positioning to become recognised as a major player in protein biomarker
discovery and application.
Pronota has an innovative protein biomarker discovery technology, which it
expects will transform the potential of protein biomarkers in molecular
diagnostics and drug discovery and development. The Company is commercialising
its proprietary MASStermind™ technology, which allows the analysis of
proteomes from biological samples, including blood, at unprecedented depth and
speed. Pronota has already secured a series of granted patents and
revenue-generating projects with pharmaceutical companies.
Protein biomarkers are useful not only for diagnosis of diseases such as
cancer, cardiovascular diseases and disorders of the central nervous system,
but also for understanding disease mechanisms, and as a basis for the
development of therapeutics. Pronota is using its protein biomarkers to
develop its own disease screens and pharmacodiagnostic products, which the
company expects will play a key role in the development of disease diagnostics
and personalised medicine.
Commenting on the name change Nick McCooke, CEO said: “Pronota’s unique
protein biomarker discovery technology represents a significant advance over
other approaches and the new name reflects our strategy to become recognised
as leading innovators in the protein biomarkers field. This name change
supports the Company’s commercial development, as we move forward to develop a
new generation of molecular diagnostics.”
- ENDS -
Notes to editors:
About Peakadilly (Pronota)
Peakadilly, which changed its name to Pronota in November 2006, was founded in
late 2004 to exploit the protein biomarker discovery technology developed at
VIB and the University of Ghent. In this short time, it has successfully
implemented the technology and won revenue generating projects with big pharma.
It applies the technology both to third party projects and to its own projects
for developing a new generation of diagnostics and pharmacodiagnostic
products.
http://www.pronota.com
For more information, please contact:
At Pronota
Nick McCooke, CEO
Pronota NV
Technologiepark 4
VIB Bio-Incubator
B-9052 Zwijnaarde / Ghent
Belgium
Tel: +32 (0)9 241 1164
nick.mccooke@pronota.com
At Northbank Communications:
(for Pronota)
Lorna Watson, Account Director
Northbank Communications Ltd
The Media Village, 131-151 Great Titchfield Street,
London, W1W 5BB, UK
Tel: +44 (0)20 3008 7559
Fax: +44 (0)20 3008 7551
Email: l.watson@northbankcommunications.com
